JAMAL I HAMMOUD
- Type
- Physician · Allopathic & Osteopathic Physicians / Internal Medicine / Endocrinology, Diabetes & Metabolism
- Where
- FLINT, MI
- NPI
- 1639284672
- Received
- $388,371 in 1,757 records, 2019 to 2025 ($386,377 general, $1,994 research)
- As principal investigator
- $2,190,984 of research payments to others in 1,394 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 201 | $41,689 |
| 2025 | Research payment | 1 | $171 |
| 2024 | General payment | 212 | $46,340 |
| 2024 | Research payment | 1 | $1,823 |
| 2023 | General payment | 239 | $58,909 |
| 2022 | General payment | 282 | $42,653 |
| 2021 | General payment | 231 | $30,597 |
| 2020 | General payment | 246 | $57,092 |
| 2019 | General payment | 344 | $109,095 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 254 | $314,151 |
| Travel and Lodging | 81 | $35,543 |
| Food and Beverage | 1,403 | $25,858 |
| Consulting Fee | 5 | $10,685 |
| Research payment | 2 | $1,994 |
| Education | 12 | $138 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-19 | Amneal Pharmaceuticals LLC | $14 | Food and Beverage | In-kind items and services | UNITHROID Drug, ENDOCRINOLOGY | 2025 | |
| 2025-12-18 | Tandem Diabetes Care, Inc. | $16 | Food and Beverage | In-kind items and services | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2025 | |
| 2025-12-12 | Amgen Inc. | $14 | Food and Beverage | In-kind items and services | REPATHA Biological, Cardiovascular | 2025 | |
| 2025-12-11 | Lilly USA, LLC | $900 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | MOUNJARO Drug, Diabetes | 2025 | |
| 2025-12-11 | Abbott Laboratories | $21 | Food and Beverage | In-kind items and services | FREESTYLE LIBRE 3 Device, Diabetes Care | 2025 | |
| 2025-12-05 | Amgen Inc. | $6 | Food and Beverage | In-kind items and services | TEPEZZA Biological, Inflammation/Rare Disease | 2025 | |
| 2025-12-03 | Ascendis Pharma Endocrinology Inc | $18 | Food and Beverage | In-kind items and services | Yorvipath Drug, Endocrinology | 2025 | |
| 2025-12-03 | Xeris Pharmaceuticals, Inc. | $13 | Food and Beverage | In-kind items and services | RECORLEV Drug, Adrenal steroidogenesis inhibitor | 2025 | |
| 2025-11-26 | Madrigal Pharmaceuticals | $23 | Food and Beverage | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-11-25 | Lilly USA, LLC | $1,800 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | MOUNJARO Drug, Diabetes | 2025 | |
| 2025-11-25 | Boehringer Ingelheim Pharmaceuticals, Inc. | $800 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | JARDIANCE Drug, DIABETES | 2025 | |
| 2025-11-25 | Lilly USA, LLC | $675 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | MOUNJARO Drug, Diabetes | 2025 | |
| 2025-11-24 | BETA BIONICS, INC. | $23 | Food and Beverage | In-kind items and services | iLet Bionic Pancreas Device, Automated insulin delivery system | 2025 | |
| 2025-11-21 | Abbott Laboratories | $17 | Food and Beverage | In-kind items and services | FREESTYLE LIBRE 3 Device, Diabetes Care | 2025 | |
| 2025-11-21 | Amgen Inc. | $9 | Food and Beverage | In-kind items and services | TEPEZZA Biological, Inflammation/Rare Disease | 2025 | |
| 2025-11-19 | Lilly USA, LLC | $900 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | MOUNJARO Drug, Diabetes | 2025 | |
| 2025-11-19 | Dexcom, Inc. | $22 | Food and Beverage | In-kind items and services | Dexcom G6 Transmitter Medical Supply, Endocrinology | 2025 | |
| 2025-11-18 | Madrigal Pharmaceuticals | $19 | Food and Beverage | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-11-18 | BETA BIONICS, INC. | $17 | Food and Beverage | In-kind items and services | iLet Bionic Pancreas Device, Automated insulin delivery system | 2025 | |
| 2025-11-18 | BETA BIONICS, INC. | $12 | Food and Beverage | In-kind items and services | iLet Bionic Pancreas Device, Automated insulin delivery system | 2025 | |
| 2025-11-18 | BETA BIONICS, INC. | $12 | Food and Beverage | In-kind items and services | iLet Bionic Pancreas Device, Automated insulin delivery system | 2025 | |
| 2025-11-18 | BETA BIONICS, INC. | $9 | Food and Beverage | In-kind items and services | iLet Bionic Pancreas Device, Automated insulin delivery system | 2025 | |
| 2025-11-18 | BETA BIONICS, INC. | $1 | Food and Beverage | In-kind items and services | iLet Bionic Pancreas Device, Automated insulin delivery system | 2025 | |
| 2025-11-18 | BETA BIONICS, INC. | $1 | Food and Beverage | In-kind items and services | iLet Bionic Pancreas Device, Automated insulin delivery system | 2025 | |
| 2025-11-17 | Amgen Inc. | $11 | Food and Beverage | In-kind items and services | REPATHA Biological, Cardiovascular | 2025 | |
| 2025-11-13 | Madrigal Pharmaceuticals | $27 | Food and Beverage | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-11-13 | GlaxoSmithKline, LLC. | $17 | Food and Beverage | In-kind items and services | AREXVY Biological, RESPIRATORY | 2025 | |
| 2025-11-11 | Xeris Pharmaceuticals, Inc. | $15 | Food and Beverage | In-kind items and services | GVOKE HYPOPEN Drug, Diabetes | 2025 | |
| 2025-11-07 | Amgen Inc. | $7 | Food and Beverage | In-kind items and services | TEPEZZA Biological, Inflammation/Rare Disease | 2025 | |
| 2025-11-06 | Corcept Therapeutics | $18 | Food and Beverage | In-kind items and services | Korlym Drug, Endocrinology | 2025 | |
| 2025-11-05 | Lilly USA, LLC | $900 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | MOUNJARO Drug, Diabetes | 2025 | |
| 2025-11-05 | Amgen Inc. | $16 | Food and Beverage | In-kind items and services | EVENITY Biological, Bone Health | 2025 | |
| 2025-10-30 | Lilly USA, LLC | $900 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | MOUNJARO Drug, Diabetes | 2025 | |
| 2025-10-30 | Novo Nordisk Inc | $16 | Food and Beverage | In-kind items and services | Rybelsus Drug, Diabetes | 2025 | |
| 2025-10-22 | Lilly USA, LLC | $1,800 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | MOUNJARO Drug, Diabetes | 2025 | |
| 2025-10-22 | Novo Nordisk Inc | $1,395 | Consulting Fee | Cash or cash equivalent | Drug, Multiple Therapeutic Areas | 2025 | |
| 2025-10-22 | Lilly USA, LLC | $1,125 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | MOUNJARO Drug, Diabetes | 2025 | |
| 2025-10-22 | Dexcom, Inc. | $23 | Food and Beverage | In-kind items and services | Dexcom G6 Transmitter Medical Supply, Endocrinology | 2025 | |
| 2025-10-22 | Amgen Inc. | $6 | Food and Beverage | In-kind items and services | TEPEZZA Biological, Inflammation/Rare Disease | 2025 | |
| 2025-10-21 | Novo Nordisk Inc | $1,395 | Consulting Fee | Cash or cash equivalent | Drug, Multiple Therapeutic Areas | 2025 | |
| 2025-10-21 | Lilly USA, LLC | $900 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | MOUNJARO Drug, Diabetes | 2025 | |
| 2025-10-20 | Lilly USA, LLC | $706 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-10-20 | Lilly USA, LLC | $2 | Food and Beverage | In-kind items and services | MOUNJARO Drug, Diabetes | 2025 | |
| 2025-10-20 | Lilly USA, LLC | $2 | Food and Beverage | In-kind items and services | MOUNJARO Drug, Diabetes | 2025 | |
| 2025-10-18 | Lilly USA, LLC | $19 | Food and Beverage | In-kind items and services | MOUNJARO Drug, Diabetes | 2025 | |
| 2025-10-17 | Lilly USA, LLC | $1,800 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | MOUNJARO Drug, Diabetes | 2025 | |
| 2025-10-17 | Lilly USA, LLC | $675 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | MOUNJARO Drug, Diabetes | 2025 | |
| 2025-10-17 | Amgen Inc. | $8 | Food and Beverage | In-kind items and services | TEPEZZA Biological, Inflammation/Rare Disease | 2025 | |
| 2025-10-16 | Madrigal Pharmaceuticals | $16 | Food and Beverage | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-10-15 | Corcept Therapeutics | $17 | Food and Beverage | In-kind items and services | Korlym Drug, Endocrinology | 2025 | |
| 2025-10-14 | Lilly USA, LLC | $1,800 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | MOUNJARO Drug, Diabetes | 2025 | |
| 2025-10-14 | Lilly USA, LLC | $1,800 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | MOUNJARO Drug, Diabetes | 2025 | |
| 2025-10-14 | Lilly USA, LLC | $1,800 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | MOUNJARO Drug, Diabetes | 2025 | |
| 2025-10-14 | Lilly USA, LLC | $675 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | MOUNJARO Drug, Diabetes | 2025 | |
| 2025-10-13 | Lilly USA, LLC | $17 | Food and Beverage | In-kind items and services | MOUNJARO Drug, Diabetes | 2025 | |
| 2025-10-13 | Amgen Inc. | $13 | Food and Beverage | In-kind items and services | REPATHA Biological, Cardiovascular | 2025 | |
| 2025-10-09 | Lilly USA, LLC | $23 | Food and Beverage | In-kind items and services | MOUNJARO Drug, Diabetes | 2025 | |
| 2025-10-09 | Xeris Pharmaceuticals, Inc. | $10 | Food and Beverage | In-kind items and services | RECORLEV Drug, Adrenal steroidogenesis inhibitor | 2025 | |
| 2025-10-06 | Lilly USA, LLC | $21 | Food and Beverage | In-kind items and services | MOUNJARO Drug, Diabetes | 2025 | |
| 2025-10-06 | Novo Nordisk Inc | $16 | Food and Beverage | In-kind items and services | Rybelsus Drug, Diabetes | 2025 | |
| 2025-10-02 | Amgen Inc. | $7 | Food and Beverage | In-kind items and services | TEPEZZA Biological, Inflammation/Rare Disease | 2025 | |
| 2025-10-01 | Ascendis Pharma Endocrinology Inc | $19 | Food and Beverage | In-kind items and services | Yorvipath Drug, Endocrinology | 2025 | |
| 2025-09-30 | Abbott Laboratories | $24 | Food and Beverage | In-kind items and services | FREESTYLE LIBRE 3 Device, Diabetes Care | 2025 | |
| 2025-09-29 | Lilly USA, LLC | $16 | Food and Beverage | In-kind items and services | MOUNJARO Drug, Diabetes | 2025 | |
| 2025-09-26 | Teleflex LLC | $53 | Food and Beverage | In-kind items and services | BARRIGEL Device, INTERVENTIONAL UROLOGY | 2025 | |
| 2025-09-26 | Corcept Therapeutics | $4 | Food and Beverage | In-kind items and services | Korlym Drug, Endocrinology | 2025 | |
| 2025-09-25 | RECORDATI_RARE_DISEASES_INC. | $32 | Food and Beverage | In-kind items and services | ISTURISA Drug, ENDOCRINE AGENT | 2025 | |
| 2025-09-18 | Amgen Inc. | $18 | Food and Beverage | In-kind items and services | EVENITY Biological, Bone Health | 2025 | |
| 2025-09-17 | BETA BIONICS, INC. | $68 | Food and Beverage | In-kind items and services | iLet Bionic Pancreas Device, Automated insulin delivery system | 2025 | |
| 2025-09-17 | BETA BIONICS, INC. | $23 | Food and Beverage | In-kind items and services | iLet Bionic Pancreas Device, Automated insulin delivery system | 2025 | |
| 2025-09-17 | Novo Nordisk Inc | $22 | Food and Beverage | In-kind items and services | Rybelsus Drug, Diabetes | 2025 | |
| 2025-09-17 | BETA BIONICS, INC. | $8 | Food and Beverage | In-kind items and services | iLet Bionic Pancreas Device, Automated insulin delivery system | 2025 | |
| 2025-09-17 | BETA BIONICS, INC. | $2 | Food and Beverage | In-kind items and services | iLet Bionic Pancreas Device, Automated insulin delivery system | 2025 | |
| 2025-09-17 | BETA BIONICS, INC. | $2 | Food and Beverage | In-kind items and services | iLet Bionic Pancreas Device, Automated insulin delivery system | 2025 | |
| 2025-09-16 | Abbott Laboratories | $7 | Food and Beverage | In-kind items and services | FREESTYLE LIBRE 3 Device, Diabetes Care | 2025 | |
| 2025-09-15 | Corcept Therapeutics | $23 | Food and Beverage | In-kind items and services | Korlym Drug, Endocrinology | 2025 | |
| 2025-09-11 | ABBVIE INC. | $17 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-09-10 | Dexcom, Inc. | $15 | Food and Beverage | In-kind items and services | Dexcom G6 Transmitter Medical Supply, Endocrinology | 2025 | |
| 2025-09-09 | GlaxoSmithKline, LLC. | $18 | Food and Beverage | In-kind items and services | AREXVY Biological, RESPIRATORY | 2025 | |
| 2025-09-04 | Amgen Inc. | $27 | Food and Beverage | In-kind items and services | EVENITY Biological, Bone Health | 2025 | |
| 2025-08-28 | Amgen Inc. | $13 | Food and Beverage | In-kind items and services | REPATHA Biological, Cardiovascular | 2025 | |
| 2025-08-27 | Radius Health, Inc. | $23 | Food and Beverage | In-kind items and services | Tymlos Drug, Endocrinology | 2025 | |
| 2025-08-27 | Abbott Laboratories | $17 | Food and Beverage | In-kind items and services | FREESTYLE LIBRE 3 Device, Diabetes Care | 2025 | |
| 2025-08-27 | Abbott Laboratories | $1 | Food and Beverage | In-kind items and services | FREESTYLE LIBRE 3 Device, Diabetes Care | 2025 | |
| 2025-08-25 | Corcept Therapeutics | $24 | Food and Beverage | In-kind items and services | Korlym Drug, Endocrinology | 2025 | |
| 2025-08-21 | BETA BIONICS, INC. | $23 | Food and Beverage | In-kind items and services | iLet Bionic Pancreas Device, Automated insulin delivery system | 2025 | |
| 2025-08-21 | BETA BIONICS, INC. | $8 | Food and Beverage | In-kind items and services | iLet Bionic Pancreas Device, Automated insulin delivery system | 2025 | |
| 2025-08-21 | BETA BIONICS, INC. | $2 | Food and Beverage | In-kind items and services | iLet Bionic Pancreas Device, Automated insulin delivery system | 2025 | |
| 2025-08-20 | Dexcom, Inc. | $17 | Food and Beverage | In-kind items and services | Dexcom G6 Transmitter Medical Supply, Endocrinology | 2025 | |
| 2025-08-14 | SANOFI-AVENTIS U.S. LLC | $16 | Food and Beverage | In-kind items and services | TZIELD Biological, Endocrine & Metabolic Diseases | 2025 | |
| 2025-08-14 | Xeris Pharmaceuticals, Inc. | $9 | Food and Beverage | In-kind items and services | RECORLEV Drug, Adrenal steroidogenesis inhibitor | 2025 | |
| 2025-08-13 | Amgen Inc. | $24 | Food and Beverage | In-kind items and services | EVENITY Biological, Bone Health | 2025 | |
| 2025-08-12 | Amneal Pharmaceuticals LLC | $17 | Food and Beverage | In-kind items and services | UNITHROID Drug, ENDOCRINOLOGY | 2025 | |
| 2025-08-04 | Lilly USA, LLC | $15 | Food and Beverage | In-kind items and services | MOUNJARO Drug, Diabetes | 2025 | |
| 2025-07-31 | Corcept Therapeutics | $37 | Food and Beverage | In-kind items and services | Korlym Drug, Endocrinology | 2025 | |
| 2025-07-29 | Xeris Pharmaceuticals, Inc. | $24 | Food and Beverage | In-kind items and services | GVOKE HYPOPEN Drug, Diabetes | 2025 | |
| 2025-07-28 | Xeris Pharmaceuticals, Inc. | $21 | Food and Beverage | In-kind items and services | RECORLEV Drug, Adrenal steroidogenesis inhibitor | 2025 | |
| 2025-07-24 | Boehringer Ingelheim Pharmaceuticals, Inc. | $800 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | JARDIANCE Drug, DIABETES | 2025 | |
| 2025-07-24 | Boehringer Ingelheim Pharmaceuticals, Inc. | $800 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | JARDIANCE Drug, DIABETES | 2025 | |
| 2025-07-23 | Boehringer Ingelheim Pharmaceuticals, Inc. | $19 | Food and Beverage (2 payments) | In-kind items and services | JARDIANCE Drug, DIABETES | 2025 | |
| 2025-07-22 | Verity Pharmaceuticals Inc. | $27 | Food and Beverage | Cash or cash equivalent | Tlando Drug, Testosterone Replacement Therapy (TRT) | 2025 | |
| 2025-07-21 | Amgen Inc. | $12 | Food and Beverage | In-kind items and services | REPATHA Biological, Cardiovascular | 2025 | |
| 2025-07-17 | Dexcom, Inc. | $20 | Food and Beverage | In-kind items and services | Dexcom G6 Transmitter Medical Supply, Endocrinology | 2025 | |
| 2025-07-17 | Xeris Pharmaceuticals, Inc. | $11 | Food and Beverage | In-kind items and services | RECORLEV Drug, Adrenal steroidogenesis inhibitor | 2025 | |
| 2025-07-16 | Amgen Inc. | $19 | Food and Beverage | In-kind items and services | EVENITY Biological, Bone Health | 2025 | |
| 2025-07-14 | Boehringer Ingelheim Pharmaceuticals, Inc. | $800 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | JARDIANCE Drug, DIABETES | 2025 | |
| 2025-07-14 | RECORDATI_RARE_DISEASES_INC. | $25 | Food and Beverage | In-kind items and services | ISTURISA Drug, ENDOCRINE AGENT | 2025 | |
| 2025-07-11 | ABBVIE INC. | $19 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-07-10 | Amgen Inc. | $17 | Food and Beverage | In-kind items and services | TEPEZZA Biological, Inflammation/Rare Disease | 2025 | |
| 2025-07-09 | Corcept Therapeutics | $23 | Food and Beverage | In-kind items and services | Korlym Drug, Endocrinology | 2025 | |
| 2025-07-03 | BETA BIONICS, INC. | $28 | Food and Beverage | In-kind items and services | iLet Bionic Pancreas Device, Automated insulin delivery system | 2025 | |
| 2025-07-03 | BETA BIONICS, INC. | $26 | Food and Beverage | In-kind items and services | iLet Bionic Pancreas Device, Automated insulin delivery system | 2025 | |
| 2025-07-03 | BETA BIONICS, INC. | $2 | Food and Beverage | In-kind items and services | iLet Bionic Pancreas Device, Automated insulin delivery system | 2025 | |
| 2025-07-02 | Alvogen Inc | $17 | Food and Beverage | In-kind items and services | TERIPARATIDE Drug, OSTEOPOROSIS | 2025 | |
| 2025-06-25 | Novo Nordisk Inc | $21 | Food and Beverage | In-kind items and services | Rybelsus Drug, Diabetes | 2025 | |
| 2025-06-24 | Lilly USA, LLC | $900 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | MOUNJARO Drug, Diabetes | 2025 | |
| 2025-06-23 | Lilly USA, LLC | $35 | Travel and Lodging | Cash or cash equivalent | MOUNJARO Drug, Diabetes | 2025 | |
| 2025-06-19 | Medtronic, Inc. | $15 | Food and Beverage | In-kind items and services | MINIMED 780G Device, Durable Pump | 2025 | |
| 2025-06-18 | Corcept Therapeutics | $20 | Food and Beverage | In-kind items and services | Korlym Drug, Endocrinology | 2025 | |
| 2025-06-16 | Lilly USA, LLC | $11 | Food and Beverage | In-kind items and services | MOUNJARO Drug, Diabetes | 2025 | |
| 2025-06-13 | Lilly USA, LLC | $1,800 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | MOUNJARO Drug, Diabetes | 2025 | |
| 2025-06-13 | Lilly USA, LLC | $675 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | MOUNJARO Drug, Diabetes | 2025 | |
| 2025-06-10 | Ascendis Pharma Endocrinology Inc | $20 | Food and Beverage | In-kind items and services | Yorvipath Drug, Endocrinology | 2025 | |
| 2025-06-09 | RECORDATI_RARE_DISEASES_INC. | $27 | Food and Beverage | In-kind items and services | ISTURISA Drug, ENDOCRINE AGENT | 2025 | |
| 2025-06-05 | Abbott Laboratories | $23 | Food and Beverage | In-kind items and services | FREESTYLE LIBRE 3 Device, Diabetes Care | 2025 | |
| 2025-06-05 | Amgen Inc. | $21 | Food and Beverage | In-kind items and services | TEPEZZA Biological, Inflammation/Rare Disease | 2025 | |
| 2025-05-29 | Amgen Inc. | $14 | Food and Beverage | In-kind items and services | REPATHA Biological, Cardiovascular | 2025 | |
| 2025-05-28 | Corcept Therapeutics | $15 | Food and Beverage | In-kind items and services | Korlym Drug, Endocrinology | 2025 | |
| 2025-05-28 | Corcept Therapeutics | $11 | Food and Beverage | In-kind items and services | Korlym Drug, Endocrinology | 2025 | |
| 2025-05-16 | Amgen Inc. | $7 | Food and Beverage | In-kind items and services | TEPEZZA Biological, Inflammation/Rare Disease | 2025 | |
| 2025-05-15 | Boehringer Ingelheim Pharmaceuticals, Inc. | $19 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2025 | |
| 2025-05-14 | Xeris Pharmaceuticals, Inc. | $22 | Food and Beverage | In-kind items and services | RECORLEV Drug, Adrenal steroidogenesis inhibitor | 2025 | |
| 2025-05-14 | Corcept Therapeutics | $4 | Food and Beverage | In-kind items and services | Korlym Drug, Endocrinology | 2025 | |
| 2025-05-13 | Novo Nordisk Inc | $8 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2025 | |
| 2025-05-13 | Amgen Inc. | $2 | Food and Beverage | In-kind items and services | TEPEZZA Biological, Inflammation/Rare Disease | 2025 | |
| 2025-05-12 | Dexcom, Inc. | $25 | Food and Beverage | In-kind items and services | Dexcom G6 Transmitter Medical Supply, Endocrinology | 2025 | |
| 2025-05-12 | Lilly USA, LLC | $17 | Food and Beverage | In-kind items and services | MOUNJARO Drug, Diabetes | 2025 | |
| 2025-05-12 | Abbott Laboratories | $15 | Food and Beverage | In-kind items and services | FREESTYLE LIBRE 3 Device, Diabetes Care | 2025 | |
| 2025-05-08 | ABBVIE INC. | $13 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-05-07 | Novo Nordisk Inc | $20 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2025 | |
| 2025-05-01 | Amgen Inc. | $18 | Food and Beverage | In-kind items and services | TEPEZZA Biological, Inflammation/Rare Disease | 2025 | |
| 2025-05-01 | Amgen Inc. | $15 | Food and Beverage | In-kind items and services | EVENITY Biological, Bone Health | 2025 | |
| 2025-04-30 | Corcept Therapeutics | $21 | Food and Beverage | In-kind items and services | Korlym Drug, Endocrinology | 2025 | |
| 2025-04-28 | Amgen Inc. | $13 | Food and Beverage | In-kind items and services | REPATHA Biological, Cardiovascular | 2025 | |
| 2025-04-24 | Boehringer Ingelheim Pharmaceuticals, Inc. | $31 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2025 | |
| 2025-04-24 | Xeris Pharmaceuticals, Inc. | $11 | Food and Beverage | In-kind items and services | RECORLEV Drug, Adrenal steroidogenesis inhibitor | 2025 | |
| 2025-04-23 | Lilly USA, LLC | $1,800 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | MOUNJARO Drug, Diabetes | 2025 | |
| 2025-04-23 | Lilly USA, LLC | $1,125 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | MOUNJARO Drug, Diabetes | 2025 | |
| 2025-04-17 | Lilly USA, LLC | $556 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-04-17 | Lilly USA, LLC | $124 | Food and Beverage | Cash or cash equivalent | MOUNJARO Drug, Diabetes | 2025 | |
| 2025-04-17 | Xeris Pharmaceuticals, Inc. | $18 | Food and Beverage | In-kind items and services | RECORLEV Drug, Adrenal steroidogenesis inhibitor | 2025 | |
| 2025-04-16 | Novo Nordisk Inc | $28 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2025 | |
| 2025-04-14 | Boehringer Ingelheim Pharmaceuticals, Inc. | $5 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2025 | |
| 2025-04-04 | Amgen Inc. | $14 | Food and Beverage | In-kind items and services | TEPEZZA Biological, Inflammation/Rare Disease | 2025 | |
| 2025-03-27 | Amgen Inc. | $21 | Food and Beverage | In-kind items and services | EVENITY Biological, Bone Health | 2025 | |
| 2025-03-24 | Radius Health, Inc. | $16 | Food and Beverage | In-kind items and services | Tymlos Drug, Endocrinology | 2025 | |
| 2025-03-21 | Boehringer Ingelheim Pharmaceuticals, Inc. | $9 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2025 | |
| 2025-03-20 | Azurity Pharmaceuticals, Inc. | $14 | Food and Beverage | In-kind items and services | AZMIRO Drug, ENDOCRINOLOGY | 2025 | |
| 2025-03-19 | Corcept Therapeutics | $16 | Food and Beverage | In-kind items and services | Korlym Drug, Endocrinology | 2025 | |
| 2025-03-18 | Amgen Inc. | $12 | Food and Beverage | In-kind items and services | EVENITY Biological, Bone Health | 2025 | |
| 2025-03-17 | Lilly USA, LLC | $800 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | JARDIANCE Drug, Diabetes | 2025 | |
| 2025-03-17 | Acella Pharmaceuticals, LLC | $13 | Food and Beverage | In-kind items and services | NP Thyroid 60 Drug, Hypothyroidism | 2025 | |
| 2025-03-13 | ABBVIE INC. | $15 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-03-12 | Abbott Laboratories | $18 | Food and Beverage | In-kind items and services | FREESTYLE LIBRE 3 Device, Diabetes Care | 2025 | |
| 2025-03-10 | Lilly USA, LLC | $800 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | JARDIANCE Drug, Diabetes | 2025 | |
| 2025-03-10 | EVOKE PHARMA, INC. | $15 | Food and Beverage | In-kind items and services | GIMOTI Drug, Gastroenterology | 2025 | |
| 2025-03-06 | Lilly USA, LLC | $21 | Food and Beverage | In-kind items and services | MOUNJARO Drug, Diabetes | 2025 | |
| 2025-03-04 | Amgen Inc. | $16 | Food and Beverage | In-kind items and services | TEPEZZA Biological, Inflammation/Rare Disease | 2025 | |
| 2025-03-03 | Amgen Inc. | $9 | Food and Beverage | In-kind items and services | REPATHA Biological, Cardiovascular | 2025 | |
| 2025-02-28 | Lilly USA, LLC | $55 | Travel and Lodging | Cash or cash equivalent | MOUNJARO Drug, Diabetes | 2025 | |
| 2025-02-28 | Lilly USA, LLC | $21 | Food and Beverage | Cash or cash equivalent | MOUNJARO Drug, Diabetes | 2025 | |
| 2025-02-28 | Corcept Therapeutics | $5 | Food and Beverage | In-kind items and services | Korlym Drug, Endocrinology | 2025 | |
| 2025-02-27 | Ascendis Pharma Endocrinology Inc | $17 | Food and Beverage | In-kind items and services | Yorvipath Drug, Endocrinology | 2025 | |
| 2025-02-26 | Xeris Pharmaceuticals, Inc. | $23 | Food and Beverage | In-kind items and services | RECORLEV Drug, Adrenal steroidogenesis inhibitor | 2025 | |
| 2025-02-25 | Novo Nordisk Inc | $2 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2025 | |
| 2025-02-24 | Abbott Laboratories | $23 | Food and Beverage | In-kind items and services | FREESTYLE LIBRE 3 Device, Diabetes Care | 2025 | |
| 2025-02-20 | Lilly USA, LLC | $21 | Food and Beverage | Cash or cash equivalent | MOUNJARO Drug, Diabetes | 2025 | |
| 2025-02-19 | Lilly USA, LLC | $3,600 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | MOUNJARO Drug, Diabetes | 2025 | |
| 2025-02-19 | Corcept Therapeutics | $22 | Food and Beverage | In-kind items and services | Korlym Drug, Endocrinology | 2025 | |
| 2025-02-18 | Novo Nordisk Inc | $4 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2025 | |
| 2025-02-12 | KYOWA KIRIN, INC. | $24 | Food and Beverage | In-kind items and services | CRYSVITA Drug, FIBROBLAST GROWTH FACTOR 23 FGF23 BLOCKING ANTIBODY | 2025 | |
| 2025-02-10 | Medtronic, Inc. | $20 | Food and Beverage | In-kind items and services | MINIMED 780G Device, Durable Pump | 2025 | |
| 2025-02-06 | Lilly USA, LLC | $659 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-02-06 | Lilly USA, LLC | $364 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-02-06 | Lilly USA, LLC | $352 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-02-06 | Lilly USA, LLC | $79 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-02-05 | Radius Health, Inc. | $23 | Food and Beverage | In-kind items and services | Tymlos Drug, Endocrinology | 2025 | |
| 2025-02-03 | Novo Nordisk Inc | $25 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2025 | |
| 2025-02-01 | Amgen Inc. | $14 | Food and Beverage | In-kind items and services | TEPEZZA Biological, Inflammation/Rare Disease | 2025 | |
| 2025-01-30 | Xeris Pharmaceuticals, Inc. | $11 | Food and Beverage | In-kind items and services | RECORLEV Drug, Adrenal steroidogenesis inhibitor | 2025 | |
| 2025-01-29 | Corcept Therapeutics | $27 | Food and Beverage | In-kind items and services | Korlym Drug, Endocrinology | 2025 | |
| 2025-01-27 | Xeris Pharmaceuticals, Inc. | $18 | Food and Beverage | In-kind items and services | RECORLEV Drug, Adrenal steroidogenesis inhibitor | 2025 | |
| 2025-01-24 | Amneal Pharmaceuticals LLC | $28 | Food and Beverage | In-kind items and services | UNITHROID Drug, ENDOCRINOLOGY | 2025 | |
| 2025-01-23 | Radius Health, Inc. | $15 | Food and Beverage | In-kind items and services | Tymlos Drug, Endocrinology | 2025 | |
| 2025-01-22 | Eli Lilly and Company | $171 | Research payment | In-kind items and services | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF VOLENRELAXIN IN | 2025 | |
| 2025-01-22 | Boehringer Ingelheim Pharmaceuticals, Inc. | $24 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2025 | |
| 2025-01-20 | Neurocrine BioSciences, Inc. | $30 | Food and Beverage | In-kind items and services | CRENESSITY Drug, Neuropsychiatry | 2025 | |
| 2025-01-10 | Corcept Therapeutics | $17 | Food and Beverage | In-kind items and services | Korlym Drug, Endocrinology | 2025 | |
| 2025-01-09 | ABBVIE INC. | $20 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-01-09 | Xeris Pharmaceuticals, Inc. | $13 | Food and Beverage | In-kind items and services | RECORLEV Drug, Adrenal steroidogenesis inhibitor | 2025 |
The latest 200 records of 1,757.
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-12-31 | ABBVIE INC. | ELITE RESEARCH CENTER LLC | $5,587 | A Phase 2/3 multicenter, double blinded, randomized, dose-conversion, active control study examining the efficacy and sa | 2025 |
| 2025-12-15 | Boehringer Ingelheim Pharmaceuticals, Inc. | ELITE CLINICAL RESEARCH | $1,706 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-12-15 | Boehringer Ingelheim Pharmaceuticals, Inc. | ELITE CLINICAL RESEARCH | $2,093 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-12-15 | Boehringer Ingelheim Pharmaceuticals, Inc. | ELITE CLINICAL RESEARCH | $17,418 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-12-05 | ABBVIE INC. | ELITE RESEARCH CENTER LLC | $16,802 | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary H | 2025 |
| 2025-12-01 | Boehringer Ingelheim International GmbH | ELITE CLINICAL RESEARCH | $39 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-12-01 | Boehringer Ingelheim International GmbH | ELITE CLINICAL RESEARCH | $39 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-12-01 | Boehringer Ingelheim Pharmaceuticals, Inc. | ELITE CLINICAL RESEARCH | $14,381 | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined u | 2025 |
| 2025-12-01 | Boehringer Ingelheim International GmbH | ELITE CLINICAL RESEARCH | $47 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-12-01 | Boehringer Ingelheim International GmbH | ELITE CLINICAL RESEARCH | $39 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-12-01 | Boehringer Ingelheim International GmbH | ELITE CLINICAL RESEARCH | $39 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-12-01 | Boehringer Ingelheim International GmbH | ELITE CLINICAL RESEARCH | $39 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-12-01 | Boehringer Ingelheim International GmbH | ELITE CLINICAL RESEARCH | $47 | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined u | 2025 |
| 2025-11-05 | ABBVIE INC. | ELITE RESEARCH CENTER LLC | $21,903 | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary H | 2025 |
| 2025-11-05 | Boehringer Ingelheim Pharma GmbH & Co.KG | ELITE CLINICAL RESEARCH | $1,669 | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined u | 2025 |
| 2025-11-01 | Boehringer Ingelheim International GmbH | ELITE CLINICAL RESEARCH | $39 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-11-01 | Boehringer Ingelheim International GmbH | ELITE CLINICAL RESEARCH | $47 | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined u | 2025 |
| 2025-11-01 | Boehringer Ingelheim International GmbH | ELITE CLINICAL RESEARCH | $39 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-11-01 | Boehringer Ingelheim International GmbH | ELITE CLINICAL RESEARCH | $39 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-11-01 | Boehringer Ingelheim International GmbH | ELITE CLINICAL RESEARCH | $39 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-11-01 | Boehringer Ingelheim International GmbH | ELITE CLINICAL RESEARCH | $47 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-11-01 | Boehringer Ingelheim International GmbH | ELITE CLINICAL RESEARCH | $39 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-10-29 | Boehringer Ingelheim Pharmaceuticals, Inc. | ELITE CLINICAL RESEARCH | $13,323 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-10-27 | Boehringer Ingelheim International GmbH | ELITE CLINICAL RESEARCH | $659 | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined u | 2025 |
| 2025-10-09 | ABBVIE INC. | ELITE RESEARCH CENTER LLC | $12,816 | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary H | 2025 |
| 2025-10-06 | Boehringer Ingelheim Pharmaceuticals, Inc. | ELITE CLINICAL RESEARCH | $2,500 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-10-01 | Boehringer Ingelheim International GmbH | ELITE CLINICAL RESEARCH | $39 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-10-01 | Boehringer Ingelheim International GmbH | ELITE CLINICAL RESEARCH | $39 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-10-01 | Boehringer Ingelheim International GmbH | ELITE CLINICAL RESEARCH | $39 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-10-01 | Boehringer Ingelheim International GmbH | ELITE CLINICAL RESEARCH | $39 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-10-01 | Boehringer Ingelheim International GmbH | ELITE CLINICAL RESEARCH | $39 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-10-01 | Boehringer Ingelheim International GmbH | ELITE CLINICAL RESEARCH | $47 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-10-01 | Boehringer Ingelheim Pharmaceuticals, Inc. | ELITE CLINICAL RESEARCH | $7,649 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-10-01 | Boehringer Ingelheim Pharmaceuticals, Inc. | ELITE CLINICAL RESEARCH | $400 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-10-01 | Boehringer Ingelheim International GmbH | ELITE CLINICAL RESEARCH | $47 | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined u | 2025 |
| 2025-10-01 | Boehringer Ingelheim Pharmaceuticals, Inc. | ELITE CLINICAL RESEARCH | $2,291 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-09-29 | Boehringer Ingelheim Pharmaceuticals, Inc. | ELITE CLINICAL RESEARCH | $269 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-09-26 | Boehringer Ingelheim Pharmaceuticals, Inc. | ELITE CLINICAL RESEARCH | $3,907 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-09-26 | Boehringer Ingelheim Pharma GmbH & Co.KG | ELITE CLINICAL RESEARCH | $1,669 | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined u | 2025 |
| 2025-09-24 | Boehringer Ingelheim International GmbH | ELITE CLINICAL RESEARCH | $27 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-09-24 | Boehringer Ingelheim International GmbH | ELITE CLINICAL RESEARCH | $116 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-09-24 | Boehringer Ingelheim International GmbH | ELITE CLINICAL RESEARCH | $319 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-09-24 | Boehringer Ingelheim International GmbH | ELITE CLINICAL RESEARCH | $1,569 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-09-24 | Boehringer Ingelheim International GmbH | ELITE CLINICAL RESEARCH | $663 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-09-24 | Boehringer Ingelheim International GmbH | ELITE CLINICAL RESEARCH | $64 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-09-18 | Boehringer Ingelheim Pharmaceuticals, Inc. | ELITE CLINICAL RESEARCH | $12,871 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-09-17 | ABBVIE INC. | ELITE RESEARCH CENTER LLC | $4,260 | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary H | 2025 |
| 2025-09-17 | ABBVIE INC. | ELITE RESEARCH CENTER LLC | $1,470 | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary H | 2025 |
| 2025-09-12 | Boehringer Ingelheim Pharmaceuticals, Inc. | ELITE CLINICAL RESEARCH | $11,500 | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined u | 2025 |
| 2025-09-04 | ABBVIE INC. | ELITE RESEARCH CENTER LLC | $13,945 | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary H | 2025 |
| 2025-09-01 | Boehringer Ingelheim International GmbH | ELITE CLINICAL RESEARCH | $39 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-09-01 | Boehringer Ingelheim International GmbH | ELITE CLINICAL RESEARCH | $47 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-09-01 | Boehringer Ingelheim International GmbH | ELITE CLINICAL RESEARCH | $47 | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined u | 2025 |
| 2025-09-01 | Boehringer Ingelheim International GmbH | ELITE CLINICAL RESEARCH | $39 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-09-01 | Boehringer Ingelheim International GmbH | ELITE CLINICAL RESEARCH | $39 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-09-01 | Boehringer Ingelheim International GmbH | ELITE CLINICAL RESEARCH | $39 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-09-01 | Boehringer Ingelheim International GmbH | ELITE CLINICAL RESEARCH | $39 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-08-06 | Boehringer Ingelheim Pharmaceuticals, Inc. | ELITE CLINICAL RESEARCH | $23,873 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-08-06 | ABBVIE INC. | ELITE RESEARCH CENTER LLC | $13,429 | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary H | 2025 |
| 2025-08-06 | Boehringer Ingelheim Pharma GmbH & Co.KG | ELITE CLINICAL RESEARCH | $6,676 | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined u | 2025 |
| 2025-08-01 | Boehringer Ingelheim International GmbH | ELITE CLINICAL RESEARCH | $30 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-08-01 | Boehringer Ingelheim International GmbH | ELITE CLINICAL RESEARCH | $39 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-08-01 | Boehringer Ingelheim International GmbH | ELITE CLINICAL RESEARCH | $39 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-08-01 | Boehringer Ingelheim International GmbH | ELITE CLINICAL RESEARCH | $39 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-08-01 | Boehringer Ingelheim International GmbH | ELITE CLINICAL RESEARCH | $39 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-08-01 | Boehringer Ingelheim International GmbH | ELITE CLINICAL RESEARCH | $39 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-08-01 | Boehringer Ingelheim International GmbH | ELITE CLINICAL RESEARCH | $47 | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined u | 2025 |
| 2025-08-01 | Boehringer Ingelheim International GmbH | ELITE CLINICAL RESEARCH | $47 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-07-31 | Boehringer Ingelheim Pharmaceuticals, Inc. | ELITE CLINICAL RESEARCH | $15,254 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-07-30 | Boehringer Ingelheim Pharmaceuticals, Inc. | ELITE CLINICAL RESEARCH | $750 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-07-30 | Boehringer Ingelheim Pharmaceuticals, Inc. | ELITE CLINICAL RESEARCH | $425 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-07-30 | Boehringer Ingelheim Pharmaceuticals, Inc. | ELITE CLINICAL RESEARCH | $750 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-07-30 | Boehringer Ingelheim Pharmaceuticals, Inc. | ELITE CLINICAL RESEARCH | $1,898 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-07-25 | Boehringer Ingelheim Pharmaceuticals, Inc. | ELITE CLINICAL RESEARCH | $391 | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined u | 2025 |
| 2025-07-25 | Boehringer Ingelheim Pharmaceuticals, Inc. | ELITE CLINICAL RESEARCH | $750 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-07-25 | Boehringer Ingelheim Pharmaceuticals, Inc. | ELITE CLINICAL RESEARCH | $750 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-07-25 | Boehringer Ingelheim Pharmaceuticals, Inc. | ELITE CLINICAL RESEARCH | $5,075 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-07-09 | Boehringer Ingelheim Pharmaceuticals, Inc. | ELITE CLINICAL RESEARCH | $1,785 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-07-02 | ABBVIE INC. | ELITE RESEARCH CENTER LLC | $13,477 | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary H | 2025 |
| 2025-07-01 | Boehringer Ingelheim International GmbH | ELITE CLINICAL RESEARCH | $47 | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined u | 2025 |
| 2025-07-01 | Boehringer Ingelheim International GmbH | ELITE CLINICAL RESEARCH | $47 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-07-01 | Boehringer Ingelheim International GmbH | ELITE CLINICAL RESEARCH | $39 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-07-01 | Boehringer Ingelheim International GmbH | ELITE CLINICAL RESEARCH | $39 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-07-01 | Boehringer Ingelheim International GmbH | ELITE CLINICAL RESEARCH | $39 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-07-01 | Boehringer Ingelheim International GmbH | ELITE CLINICAL RESEARCH | $39 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-07-01 | Boehringer Ingelheim International GmbH | ELITE CLINICAL RESEARCH | $39 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-06-26 | Boehringer Ingelheim Pharmaceuticals, Inc. | ELITE CLINICAL RESEARCH | $18,619 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-06-25 | ABBVIE INC. | ELITE RESEARCH CENTER LLC | $1,069 | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary H | 2025 |
| 2025-06-18 | ABBVIE INC. | ELITE RESEARCH CENTER LLC | $2,500 | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary H | 2025 |
| 2025-06-12 | Boehringer Ingelheim Pharmaceuticals, Inc. | ELITE CLINICAL RESEARCH | $575 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-06-03 | ABBVIE INC. | ELITE RESEARCH CENTER LLC | $22,195 | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary H | 2025 |
| 2025-06-01 | Boehringer Ingelheim International GmbH | ELITE CLINICAL RESEARCH | $39 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-06-01 | Boehringer Ingelheim International GmbH | ELITE CLINICAL RESEARCH | $39 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-06-01 | Boehringer Ingelheim International GmbH | ELITE CLINICAL RESEARCH | $39 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-06-01 | Boehringer Ingelheim International GmbH | ELITE CLINICAL RESEARCH | $39 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-06-01 | Boehringer Ingelheim International GmbH | ELITE CLINICAL RESEARCH | $172 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-06-01 | Boehringer Ingelheim International GmbH | ELITE CLINICAL RESEARCH | $47 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-06-01 | Boehringer Ingelheim International GmbH | ELITE CLINICAL RESEARCH | $23 | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined u | 2025 |
| 2025-06-01 | Boehringer Ingelheim International GmbH | ELITE CLINICAL RESEARCH | $24 | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined u | 2025 |
| 2025-06-01 | Boehringer Ingelheim International GmbH | ELITE CLINICAL RESEARCH | $47 | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined u | 2025 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Flint, MI, county Genesee County, MI, state Michigan; placed by its city name.
| Measure | Place (city or town) Flint, MI | County Genesee County, MI | State Michigan |
|---|---|---|---|
| Population B01003 | 80,175 | 403,305 | 10,077,761 |
| Population, 2020 census P1 | 81,252 | 406,211 | 10,077,331 |
| Median age B01002 | 36.9 | 40.6 | 40.2 |
| Under 18 B01001 | 23.6% | 22.2% | 21.2% |
| 65 and over B01001 | 14.1% | 18.8% | 18.6% |
| Households B11001 | 34,572 | 167,334 | 4,076,369 |
| Foreign born B05002 | 3.2% | 2.9% | 7.2% |
| Median household income B19013 | $37,646 | $62,281 | $72,875 |
| Median family income B19113 | $45,402 | $78,441 | $93,357 |
| Per capita income B19301 | $21,720 | $35,334 | $40,735 |
| Poverty rate B17001 | 34.1% | 16.4% | 13.2% |
| Unemployment rate B23025 | 14.8% | 8.1% | 5.7% |
| Civilian labor force B23025 | 34,441 | 189,612 | 5,018,449 |
| Mean commute (minutes) B08013 | 22.7 | 26.9 | 24.2 |
| Bachelor's degree or higher B15003 | 14.2% | 23.3% | 32.4% |
| Housing units B25001 | 43,028 | 183,903 | 4,622,236 |
| Owner-occupied B25003 | 53.8% | 70.7% | 73.2% |
| Renters B25003 | 46.2% | 29.3% | 26.8% |
| Median home value B25077 | $53,500 | $182,400 | $231,600 |
| Median gross rent B25064 | $915 | $989 | $1,129 |
| White, not Hispanic B03002 | 33.4% | 70.0% | 72.4% |
| Black B03002 | 55.3% | 19.1% | 13.1% |
| Hispanic or Latino B03002 | 4.5% | 4.3% | 5.9% |
| Asian B03002 | 0.7% | 1.1% | 3.4% |
| American Indian and Alaska Native B03002 | 0.3% | 0.2% | 0.3% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Flint, MI.
Comments